CDR2 and neoplasm: The antibody is often suggestive of the underlying tumor, with anti-Yo most often associated with breast or gynecological malignancies, anti-Ri associated with breast or lung malignancies, anti-PCA-2 with lung malignancies55–57, and anti-Tr and anti-mGluR1 with Hodgkin’s disease53,58,59.